Sean Monahan - PhaseRx Director of Chemistry
Director
Dr. Sean Monahan, Ph.D., is Vice President Chemistry of the Company. Dr. Monahan, joined PhaseRx as the director of chemistry in July, 2009, bringing more than ten years of experience in the area of nucleic acid delivery technologies. From 1998 to 2011, Dr. Monahan served in various capacities with Roche Mirus Bio Corporation . In this capacity, Dr. Monahan was involved in the development of both lipid and polymeric systems for the delivery of drugs and nucleic acids in both the research and product areas. From 1996 to 1998, Dr. Monahan worked in medicinal chemistry, new lead discovery, at Berlex Biosciences, the U.S. Research and Development Center for Schering AG in Germany. Dr. Monahan received a B.A. in chemistry from the University of Colorado, Boulder, and a Ph.D. in organic chemistry from the University of Wisconsin, Madison. Dr. Monahan has authored numerous papers and patents in the areas of drug and nucleic acid delivery. since 2015.
| Tenure | 9 years |
| Phone | 206-805-6300 |
| Web | http://www.phaserx.com |
PhaseRx Management Efficiency
The company has return on total asset (ROA) of (64.2) % which means that it has lost $64.2 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (228.17) %, meaning that it created substantial loss on money invested by shareholders. PhaseRx's management efficiency ratios could be used to measure how well PhaseRx manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.44 M in liabilities with Debt to Equity (D/E) ratio of 264.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PhaseRx has a current ratio of 2.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist PhaseRx until it has trouble settling it off, either with new capital or with free cash flow. So, PhaseRx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PhaseRx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PhaseRx to invest in growth at high rates of return. When we think about PhaseRx's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jan Lundberg | Ardelyx | 63 | |
| Patricia Barron | Teleflex Incorporated | 73 | |
| Thomas Williams | Chart Industries | 59 | |
| Richard Packer | Teleflex Incorporated | 62 | |
| WILLIAM Cook | Teleflex Incorporated | 71 | |
| Kim Foster | Teleflex Incorporated | 68 | |
| Ping Wong | Highway Holdings Limited | 47 | |
| Kuang Yang | Highway Holdings Limited | 56 | |
| Gordon Ringold | Ardelyx | 66 | |
| Faysal Kalmoua | Alvotech | 48 | |
| Annalisa Jenkins | Ardelyx | 51 | |
| Gretchen Haggerty | Teleflex Incorporated | 65 | |
| Richard Rodgers | Ardelyx | 49 | |
| Candace Duncan | Teleflex Incorporated | 67 | |
| Robert Bazemore | Ardelyx | 50 | |
| George Babich | Teleflex Incorporated | 69 | |
| Stuart Randle | Teleflex Incorporated | 61 | |
| Jim Fischman | Chart Industries | N/A | |
| John Heinmiller | Teleflex Incorporated | 66 | |
| Richard Goodrich | Chart Industries | 73 | |
| Michael Molinini | Chart Industries | 69 | |
Management Performance
| Return On Equity | -228.17 | |||
| Return On Asset | -64.2 |
PhaseRx Leadership Team
Elected by the shareholders, the PhaseRx's board of directors comprises two types of representatives: PhaseRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PhaseRx. The board's role is to monitor PhaseRx's management team and ensure that shareholders' interests are well served. PhaseRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PhaseRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ShingYin Tsui, Senior Vice President - Finance, Secretary | ||
| Brian Atwood, Director | ||
| Sean Monahan, Director of Chemistry | ||
| John Schmidt, Director | ||
| Pat Stayton, Co-Founder | ||
| Steven Gillis, Chairman of the Board | ||
| Richard Ulevitch, Director | ||
| Paul Johnson, Chief Scientific Officer, Co-Founder, Director | ||
| Allan Hoffman, Co-Founder | ||
| Robert Overell, Co-Founder and Presidentident, CEO, Director | ||
| Peggy Phillips, Director | ||
| Michelle Griffin, Independent Director | ||
| Michael Houston, Vice President - Therapeutics Development | ||
| Oliver Press, Co-Founder | ||
| Mary Prieve, Director of Biology | ||
| Gordon Brandt, Chief Medical Officer | ||
| James Watson, Head of Corporate Development | ||
| Erin Cox, IR Contact Officer |
PhaseRx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PhaseRx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -228.17 | |||
| Return On Asset | -64.2 | |||
| Current Valuation | 3.46 M | |||
| Shares Outstanding | 11.69 M | |||
| Shares Owned By Insiders | 11.22 % | |||
| Shares Owned By Institutions | 51.52 % | |||
| Number Of Shares Shorted | 8.39 K | |||
| Price To Earning | (0.79) X | |||
| Price To Book | 5.65 X | |||
| EBITDA | (12.96 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PhaseRx in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PhaseRx's short interest history, or implied volatility extrapolated from PhaseRx options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PhaseRx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in PhaseRx Stock
If you are still planning to invest in PhaseRx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PhaseRx's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |